TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Innate Pharma SA ( (FR:IPH) ) has shared an update.
Innate Pharma S.A. reported its third-quarter 2025 business update and financial results, highlighting significant progress in its key programs. The company received FDA clearance for the TELLOMAK-3 Phase 3 trial for lacutamab, aiming for potential accelerated approval in Sézary syndrome, and continues to advance its IPH4502 and monalizumab programs. With a cash position of €56.4 million as of September 30, 2025, Innate Pharma anticipates a cash runway until the end of Q3 2026. The company is also planning organizational streamlining, including layoffs, expected to be completed in the first half of 2026.
The most recent analyst rating on (FR:IPH) stock is a Hold with a EUR1.50 price target. To see the full list of analyst forecasts on Innate Pharma SA stock, see the FR:IPH Stock Forecast page.
More about Innate Pharma SA
Innate Pharma S.A. is a global, clinical-stage biotechnology company focused on developing immunotherapies for cancer patients. The company leverages its expertise in antibody-engineering and innovative target identification to create next-generation antibody therapeutics. Innate Pharma’s portfolio includes potential first- and/or best-in-class assets such as IPH4502, a Nectin-4 ADC for solid tumors, lacutamab for cutaneous and peripheral T cell lymphomas, and monalizumab in collaboration with AstraZeneca for non-small cell lung cancer. The company collaborates with leading biopharmaceutical companies like Sanofi and AstraZeneca and is headquartered in Marseille, France, with a US office in Rockville, MD.
Average Trading Volume: 276,873
Technical Sentiment Signal: Strong Sell
Current Market Cap: €153M
For an in-depth examination of IPH stock, go to TipRanks’ Overview page.